VanEck ETF Trust VanEck Consumer Discretionary TruSector ETF TRUD 深 滬
等待開盤 11-26 09:30:00 美东时间
25.6212
+0.488
+1.94%
華盛通- 最 高25.6212
- 今 開25.4599
- 成交量 1.08万股
- 最 低 25.4599
- 昨 收 25.1332
- 總市值 1101.71万
- 52周最高 27.19
- 市盈率 靜 --
- 換手率 2.50%
- 52周最低 24.2453
- 委 比 0.00%
- 總股本 43.00万
- 歷史最高 27.19
- 量 比 0.05
- 振 幅 0.64%
- 歷史最低 24.2453
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immutep Data From EFTISARC-NEO Study Evaluating Eftilagimod Alfa With Radiotherapy Plus KEYTRUDA Exceeds Prespecified Level Of Pathologic Response Rates, Reaches Median 51.5% Tumor Hyalinization/Fibrosis
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces positive data from the EFTISARC-NEO trial that were
11-13 21:02
CytomX Therapeutics To Present Initial Translational Data From Ongoing Phase 1 Study Of CX-801 In Patients With Advanced Melanoma At SITC Annual Meeting
- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -- Data supportive of CX-801's mechanism of action and the
11-04 22:16
Merck's Topline Data From Phase 3 LITESPARK-022 Trial Of Keytruda (Pembrolizumab) Plus Welireg (Belzutifan) In Adjuvant Setting Showed Statistically Significant And Clinically Meaningful Improvement In Disease-free Survival For Clear Cell Renal Cell Carcinoma
First combination regimen to demonstrate improvement in DFS compared to KEYTRUDA monotherapy for these patients in the adjuvant settingLITESPARK-022 is the second positive Phase 3 study for WELIREG as part of a
10-28 18:48
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 27, 2025 /PRNewswire/ -- The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce t...
10-27 20:30
IO Biotech Phase 3: Cylembio Plus KEYTRUDA Extends Median PFS To 19.4 Months In First-Line Advanced Melanoma, Showing Clinically Meaningful Improvement Despite Narrow Miss On Statistical Significance
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS)
10-20 14:48
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – MIT and Harvard scientists recently created...
10-17 21:50
Merck To Unveil Cancer Treatment Data at ESMO 2025, Featuring Key Studies on KEYTRUDA and New Antibody-Drug Conjugates
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across more than 20 types of cancer and multiple treatment settings from the company's
10-09 18:49
Merck's Keytruda Gets Green Light For New Head And Neck Cancer Use, European Approval Decision Due This Year
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for
09-19 18:48
Eli Lilly's Olomorasib + KEYTRUDA Combo Secures FDA Breakthrough Therapy Designation For KRAS G12C NSCLC With High PD-L1
The Breakthrough Therapy designation for olomorasib is based on data from the Phase 1/2 LOXO-RAS-20001 trial and Phase 3 SUNRAY-01 trialUpdated efficacy and safety data for olomorasib will be presented at the IASLC 2025
09-04 18:50
VanEck Targets Nvidia, Microsoft Weight Caps With TruSector ETFs For Tech, Consumer Sectors
VanEck has new ETFs that aim to minimize tracking error by eliminating artificial limits on leading holdings.
08-26 21:17
